Table 1 Donor characteristics and stratification of donor and recipient rats

In vitro pravastatin treatment

CKD ( n = 10)

SNX (%)

66 ± 2

Week 5 SBP (mmHg)

169 ± 28

Week 5 urea (mmol/l)

11 ± 2

Week 5 proteinuria (mg/24 hours)

18 ± 28

Donor rats

Healthy + DMEM BMC ( n = 2)

Healthy + pravastatin BMC ( n = 2)

CKD + DMEM BMC ( n = 4)

CKD + pravastatin BMC ( n = 5)

SNX (%)

–

–

64.0 ± 6.0

69.0 ± 5.5

Week 5 SBP (mmHg)

–

–

148 ± 34

152 ± 8

Week 5 urea (mmol/l)

4.6 ± 0.01

4.1 ± 0.9

15.0 ± 4.4

15.9 ± 6.9

Week 5 proteinuria (mg/24 hours)

1.4 ± 0.4

1.8 ± 0.7

24 ± 8

49 ± 46

Recipient rats

Healthy + DMEM BMC ( n = 5)

Healthy + pravastatin BMC ( n = 5)

CKD + DMEM BMC ( n = 10)

CKD + pravastatin BMC ( n = 9)

SNX (%)

66.3 ± 1.6

66.7 ± 6.4

66.5 ± 3.5

67.6 ± 7.1

Week 5 SBP (mmHg)

156 ± 15

155 ± 16

159 ± 25

155 ± 19

Week 5 urea (mmol/l)

10.1 ± 0.9

10.3 ± 1.5

12.1 ± 3.2

10.6 ± 2.3

Week 5 proteinuria (mg/24 hours)

21.6 ± 5.6

21.9 ± 6.8

23.7 ± 17.3

22.7 ± 8.4

Recipient rats

CKD + pravastatin ( n = 5)

CKD ( n = 6)

SNX (%)

69 ± 2

66 ± 3

Week 5 SBP (mmHg)

158 ± 19

159 ± 10

Week 5 urea (mmol/l)

12.7 ± 1.1

12.8 ± 1.4

Week 5 proteinuria (mg/24 hours)

14.6 ± 2.7

16.5 ± 6.6